Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer

Acta Oncologica

Volumn 53, Issue 3, 2014, Pages 385-391

  Schonnemann, Katrine R ^a,b   Mortensen, Michael B ^a,b   Bjerregaard, Jon K ^a,b   Fristrup, Claus ^a   Pfeiffer, Per ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DENMARK; ENDOSCOPIC SURGERY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FUNCTIONAL STATUS; GASTRECTOMY; GASTROESOPHAGEAL ADENOCARCINOMA; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; SURVIVAL TIME; THORAX SURGERY; VERY ELDERLY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; DYSPHAGIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DENMARK; ESOPHAGEAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84894122092     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.820839     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin 2011;61:69-90.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Cancer J Clin 2005;55:74-108.
3. Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 2009;20:885-91.
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med 2006;355:11-20.
5. Available from http://decv.gicancer.dk/Content/Files/Dokumenter/ Kliniske%20Retningslinier%202011.pdf [2013 Apr 8].
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl J Med 2008;358:36-46.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluor-ouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24:4991-7.
8. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews [Internet]. 2010;3. Available from: http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD004064/frame.html. http:// onlinelibrary.wiley. com/store/10.1002/14651858.CD004064.pub3/asset/CD004064.pdf?v = 1&t = h6yvrakr&s = eb034c 73ad0b25d258e38c5d54d7fa1140ffb145. [Cited 2013 June 2]
9. Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002;20:2109-17.
10. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115:4679-87.
11. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Danish Med Bull 1997;44:535-9.
12. Schonnemann KR, Jensen HA, Yilmaz M, Jensen BY, Larsen O, Pfeiffer P. Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. Br J Cancer 2008;99:858-61.
13. Schonnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. Eur J Cancer 2012;48:510-7.
14. Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218-31.
15. De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Belot A, et al. The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009;45: 909-30.
16. Barchielli A, Amorosi A, Balzi D, Crocetti E, Nesi G. Long-term prognosis of gastric cancer in a European country: A population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1987. Eur J Cancer 2001;37:1674-80.
17. Hansson L-E, Ekstrom A-M, Bergstrom R, Nyren O. Surgery for stomach cancer in a defined Swedish population: Current practices and operative results. Eur J Surg 2000;166: 787-95.
18. Lello E, Furnes B, Edna T-H. Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta Oncol 2007;46:308-15.
19. van de Poll-Franse LV, Lemmens VEPP, Roukema JA, Coebergh JWW, Nieuwenhuijzen GAP. Impact of concentration of oesophageal and gastric cardia cancer surgery on long-term population-based survival. Br J Surg 2011;98: 956-63.
20. Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008;14:3165-73.
21. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-21.
22. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIvB, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New Engl J Med 2012;366:2074-84.
23. Sung Wook H, Dong Ho L, Sang Hyub L, Young Soo P, Jin Hyeok H, Jin Wook K, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol 2010;25:512-8.
24. Hofheinz RD, Al-Batran SE, Ridwelski K, Gorg C, Wehle K, Birth M, et al. Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie 2010; 33:512-8.
25. Shitara K, Ikeda J, Kondo C, Takahari D, Ura T, Muro K, et al. Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer 2012;15: 137-43.